Kala Pharmaceuticals Reports Third Quarter 2022 Financial
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Ended...
Source: globenewswire.com
Ophthalmic Faculty News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ophthalmic Faculty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ophthalmic Faculty Today - Breaking & Trending Today
Kala Pharmaceuticals Announces Appointment of Marjan Farid,
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage...
Source: globenewswire.com
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain
IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain News provided by Share this article - License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies IRVINE, Calif., PARIS, HONG KONG, Jan. 7, 2021 /PRNewswire/ -- IACTA Pharmaceuticals, Inc. ("IACTA") and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with IACTA acquiring global rights to Phar...
Source: prnewswire.com